Abstract:Background: Aspirin-exacerbated respiratory disease (AERD) is associated with high levels of cysteinyl leukotrienes, prostaglandin D2, and low levels of prostaglandin E2. Further, 15-hydroxyeicosatetraenoic acid (15-HETE) levels may have predictive value in therapeutic outcomes of aspirin desensitization. Accumulation of nasal group 2 innate lymphoid cells (ILC2s) has been demonstrated during COX-1 inhibition in AERD, although the relationships between tissue ILC2 accumulation, reaction symptom severity, and novel lipid biomarkers are unknown. Objective: We sought to determine whether novel lipid mediators are predictive of nasal ILC2 accumulation and symptom scores during COX-1 inhibitor challenge in patients with AERD. Methods: Blood and nasal scraping samples from patients with AERD were collected at baseline and COX-1 inhibitor reaction and then processed for flow cytometry for nasal ILC2s and serum for lipidomic analysis. Results: Eight patients with AERD who were undergoing aspirin desensitization were recruited. Of the 161 eicosanoids tested, 42 serum mediators were detected. Baseline levels of 15-HETE were negatively correlated with the change in numbers of airway ILC2s (r = -0.6667; P = .0428). Docosahexaenoic acid epoxygenase metabolite 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid (19,20-diHDPA) was positively correlated with both changes in airway ILC2s (r = 0.7143; P = .0305) and clinical symptom scores (r = 0.5000; P = .0081). Conclusion: Low levels of baseline 15-HETE predicted a greater accumulation of airway ILC2s in patients with AERD who were receiving COX-1 inhibition. Further, increases in the cytochrome P pathway metabolite 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid (19,20-diHDPA) were associated with increased symptoms and nasal ILC2 accumulation. Future studies to assess how these mediators might control ILC2s may improve the understanding of AERD pathogenesis.

Human dendritic cells are a physiological source of the chemotactic arachidonic acid metabolite 5-oxo-eicosatetraenoic acid

5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration.

Human Monocyte-Derived Dendritic Cells Expressing Both Chemotactic Cytokines IL-8, MCP-1, RANTES and Their Receptors, and Their Selective Migration to These Chemokines.

The Formation of Phosphatidylcholine Oxidation Products by Stimulated Phagocytes

[1 Alpha, 25-Dihydroxyvitamin D3 and Its Analogues Modulate the Phagocytosis of Human Monocyte-Derived Dendritic Cells].

Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells.

Biological Roles of 5-Oxo-6,8,11,14-Eicosatetraenoic Acid and the OXE Receptor in Allergic Diseases: Collegium Internationale Allergologicum Update 2024

The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor

5-Oxo-Ete From Nasal Epithelial Cells Upregulates Eosinophil Cation Protein By Eosinophils In Nasal Polyps In Vitro

Targeting the OXE receptor as a potential novel therapy for asthma

15-Oxoeicosatetraenoic Acid Mediates Monocyte Adhesion to Endothelial Cell

Identification and quantification of metabolites of arachidonic acid from cultures of endothelial cells by HPLC-MS2

Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids.

Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates

Incorporation of eicosatrienoic acid exerts mild anti-inflammatory properties in murine RAW264.7 cells

5-Oxo-ETE/OXER1: A Link between Tumor Cells and Macrophages Leading to Regulation of Migration

Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD

Arachidonic acid: reconciling the dichotomy of its oxidative cascade through specific deuteration

Nrf2 Activation by 5-lipoxygenase Metabolites in Human Umbilical Vascular Endothelial Cells

The Role of Hydroxyeicosatetraenoic Acids in the Regulation of Inflammation in Bronchial Asthma

The Polyunsaturated Fatty Acids Arachidonic Acid and Docosahexaenoic Acid Induce Mouse Dendritic Cells Maturation but Reduce T-Cell Responses In Vitro